Back to User profile » Dr Isaac Nuamah
Papers published by Dr Isaac Nuamah:
Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis
Li G, Keenan A, Daskiran M, Mathews M, Nuamah I, Orman C, Joshi K, Singh A, Godet A, Pungor K, Gopal S
Patient Preference and Adherence 2021, 15:2239-2248
Published Date: 2 October 2021
Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire
Blackwood C, Sanga P, Nuamah I, Keenan A, Singh A, Mathews M, Gopal S
Patient Preference and Adherence 2020, 14:1093-1102
Published Date: 2 July 2020
Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies
Mathews M, Gopal S, Singh A, Nuamah I, Pungor K, Tan W, Soares B, Kim E, Savitz AJ
Neuropsychiatric Disease and Treatment 2020, 16:1533-1542
Published Date: 19 June 2020
Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
Mathews M, Gopal S, Nuamah I, Hargarter L, Savitz AJ, Kim E, Tan W, Soares B, Correll CU
Neuropsychiatric Disease and Treatment 2019, 15:1365-1379
Published Date: 21 May 2019
Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population
Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, Hargarter L
Neuropsychiatric Disease and Treatment 2019, 15:587-602
Published Date: 21 February 2019
Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
Mathe}ws M, Nuamah I, Savitz AJ, Hough DW, Najarian D, Kim E, Gopal S
Neuropsychiatric Disease and Treatment 2018, 14:2807-2816
Published Date: 25 October 2018
Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study
Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, Mathews M, Feng Y, Yu L, Takahashi M, Liu D, Wang G, Yoon J, Chen JJ
Neuropsychiatric Disease and Treatment 2017, 13:2193-2207
Published Date: 17 August 2017
Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study
Zhang H, Li H, Liu Y, Wu C, Wu Q, Nuamah I, Shi J, Xie S, Wang G, Gopal S
Neuropsychiatric Disease and Treatment 2016, 12:69-77
Published Date: 8 January 2016
Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies
Gopal S, Liu Y, Alphs L, Savitz A, Nuamah I, Hough D
Neuropsychiatric Disease and Treatment 2013, 9:1381-1392
Published Date: 20 September 2013
Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose
Samtani MN, Nuamah I, Gopal S, Remmerie B, Sliwa JK, Alphs L
Neuropsychiatric Disease and Treatment 2013, 9:721-730
Published Date: 20 May 2013
Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia
Srihari Gopal, Joris Berwaerts, Isaac Nuamah, et al
Neuropsychiatric Disease and Treatment 2011, 7:93-101
Published Date: 8 March 2011